GSA Capital Partners’s Legend Biotech LEGN Stock Holding History

GSA Capital Partners’s Portfolio LEGN Stock Details LEGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$279K	Sell	9,656 -75,109	-89%	-$2.03M	0.02%	1348
2026 Q1	$1.53M	Buy	84,765 +69,882	+470%	+$1.33M	0.1%	272
2025 Q4	$324K	Buy	+14,883	New	+$426K	0.03%	1128
2023 Q3	–	Sell	-12,296	Closed	-$849K	–	1726
2023 Q2	$849K	Buy	+12,296	New	+$803K	0.08%	409
2021 Q4	–	Sell	-6,104	Closed	-$309K	–	1623
2021 Q3	$309K	Buy	+6,104	New	+$254K	0.03%	997

Other funds holding LEGN

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return

SCM

Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return

HHLR Advisors Grand Cayman, Cayman Islands $832M AUM 32.38% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

KCM

Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return

Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.56% 1-Year Est. Return

GSA Capital Partners's LEGN Position: Q2 2026 in Review

GSA Capital Partners reduced its Legend Biotech (LEGN) stake by 89% in Q2 2026, selling an estimated $2.03M and leaving 9,656 shares worth $279K. The position accounts for 0.02% of the portfolio, ranked #1348.

GSA Capital Partners first reported a position in LEGN in Q3 2021 and has held it in 5 quarters since. The position peaked at $1.53M in Q1 2026. 219 funds tracked by Wall St. Rank hold LEGN as of Q2 2026.

GSA Capital Partners held 9,656 shares of Legend Biotech worth $279K as of Q2 2026.
GSA Capital Partners sold 75,109 Legend Biotech shares in Q2 2026, an estimated $2.03M.
Legend Biotech made up 0.02% of GSA Capital Partners's portfolio in Q2 2026, its #1348 holding.
GSA Capital Partners first reported a position in Legend Biotech in Q3 2021 and has held it in 5 quarters since.
GSA Capital Partners's Legend Biotech position peaked at $1.53M in Q1 2026.
219 funds tracked by Wall St. Rank held Legend Biotech as of Q2 2026.

Based on GSA Capital Partners's 13F filing for Q2 2026, filed 6 Aug 2026.